Below are full profiles from other companies in related areas ...

FRONTERA GROUP is a cross-functional blend of behaviour and creative engagement experts. Our approach identifies the underlying drivers of decision making, to uncover how choices are made today and ...

The companies will use Ascendis’ TransCon technology to develop therapies for metabolic and cardiovascular diseases ...

Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the European Commission (EC) to treat eosinophilic ...

Chiesi Group and Oak Hill Bio have announced that the first European patient has been enrolled in a phase 2b study evaluating ...

PharmaNet/i3, a leader in drug development services, has a global infrastructure, therapeutic expertise, and commitment to quality that is unmatched in the industry. For pharmaceutical, biotechnology, ...

The US Food and Drug Administration (FDA) has approved Journey Medical’s Emrosi (minocycline hydrochloride extended release capsules 40mg) to treat inflammatory lesions of rosacea in adults. Affecting ...

EXECUTIVE FACILITIES established for over 30 years is a ‘specialist’ recruitment consultancy run by ‘recruitment specialists’. Our highly trained Consultants, educated to degree level, have expert ...

Johnson & Johnson (J&J) has announced that its pan-FGFR tyrosine kinase inhibitor Balversa (erdafitinib) has been granted ...

GSK has announced that it will be expanding its immunology pipeline by acquiring a clinical-stage T cell-engager from ...

EatMoreFruit, a UK top 10 independent healthcare communication agency, today announced the launch of its European Network to ...

Novo Nordisk has shared promising results from a late-stage study of semaglutide in patients with metabolic dysfunction-associated steatohepatitis (MASH), a progressive metabolic disease that affects ...